CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HALCINONIDE	IM	*USP39–NF34*	4176	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
CREAM	PUR ITIES/*Organic Impuri ties/ Chromatographi c system*						*Supplement to USP40–NF35*	*Column*: Change 1.8-µm packing L1 to: 1.7-µm packing L1
NAPROXEN TABLETS	IM PUR ITIES/*Organic Impurities*	*USP39–NF34*	4993	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 6 of *Analysis*: Change Result = (r_U/r_S) × (C_U/C_S) × 100 to: Result = (r_U/r_S) × (C_S/C_U) × 100
TRIHEXYPHEN IDYL HYDROC HLORIDE EXT ENDED-RELEASE CAPSULES	*Assay*	*USP39–NF34*	6265	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 1 of *Mobile phase* and *Chromatographi c system*: Change Prepare as directed in the *Assay* under *Trihexyphenidyl Hydrochloride*. to: *Mobile phase*—Prepare a mixture of acetonitrile, water, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								triethylamine (920:80:0.2), adjust with phosphoric acid to a pH of 4.0, mix, filter, and degas. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 210-nm detector and a 4.6-mm × 8-cm column that contains 3-µm packing L1. The flow rate is about 2 mL per minute. Chromatograph the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								preparation, and record the peak responses as directed for *Procedure*: the column efficiency determined from the analyte peak is not less than 1300 theoretical plates, the tailing factor for the analyte peak is not more than 3.0, and the relative standard deviation for replicate injections is not more than 1.0%. AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Assay* under *Trihexyphenidyl Hydrochloride*. to: Separately inject equal volumes (about 10 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks. AND Line 6 of *Procedure*: Change and the other terms are as defined therein. to: *C* is the concentration, in mg per mL, of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								USP Trihexyphenidyl Hydrochloride RS in the *Standard preparation*, r_U and r_S are the trihexyphenidyl peak responses obtained from the *Assay preparation* and the *Standard preparation*, respectively.
BISOCTRIZOLE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8008	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Bisoctrizole Resolution Mixture RS: Change A mixture of approximately 1.5% of bisoctrizole isomer [phenol, 2,2-methylenebis[6-(2*H*-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)]] in a matrix of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								bisoctrizole. to: A mixture of approximately 1.5% of bisoctrizole isomer [phenol, 2,2?-methylene bis[6-(2*H*-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)]] in a matrix of bisoctrizole.
ORALLY INHALED AND NASAL DRUG PRODUCTS	REFERENCES	*USP39–NF34*	1862	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Delete reference 3.
GRANISETRON HYDROCHLORIDE INJECTION	*USP Reference standards <11>*	*USP39–NF34*	4153	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 2 of USP Granisetron Related Compound B RS: Change (*N*-[(1*R*,3*r*,5)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide). to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LOVASTATIN	*USP Reference standards <11>*	*USP39–NF34*	4631	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	*N*-[(1*R*,3*r*,5*S*)-9-Methyl-9-azabicyclo[3.3.1]non-3-yl]-1*H*-indazole-3-carboxamide. Line 2 of USP Lovastatin Related Compound A RS: Change [Dihydro-lovastatin][butanoic acid, 2-methyl-, 1,2,3,4,4a,7,8,8a-octahydro-3,7-dimethyl-8-[2(tetrahydro-4-hydrox y-6-ox o-2*H*-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1*S*-[1?(*R**), 3?,7?,8?(2*S**,4*S**),-8??]]]-. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(1*S*,3*S*,4a*R*,7*S*,8*S*,8a*S*)-8-{2-[(2*R*,4*R*)-4-hydroxy-6-oxotetrahydro-2*H*-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl (*S*)-2-methylbutanoate.
SIMVASTATIN TABLETS	IMPURITIES/*Organic Impurities/Analysis*	*USP39–NF34*	5848	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 5: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$ AND Delete the variable definitions for M_{r1} and M_{r2}.
FUMARIC ACID	SPECIFIC TESTS/*Water*	*USP39–NF34*	7309	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to*	Line 1: Change 0.5%

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Determination, Method I <921>						*USP40–NF35*	to: NMT 0.5%
NAPROXEN SODIUM TABLETS	IMPURITIES/*Organic Impurities*	*Second Supplement to USP39–NF34*	Online	29-Jul-2016	1-Aug-2016	*USP41–NF36*	*First Supplement to USP40–NF35*	Line 6 of *Analysis*: Change Result = $(r_U/r_S) \times (C_U/C_S) \times 100$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times 100$
BACITRACIN ZINC	IMPURITIES	*USP39–NF34*	2674	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Delete the *Residue on Ignition <281>* test.
LORAZEPAM INJECTION	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4620	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: $C_{13}H_9Cl_2NO$
NALTREXONE HYDROCHLORIDE	*Related compounds*	*USP39–NF34*	4985	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 5: Change $10F(C/W)(r_U / r_S)$ to: $1000F(C/W)(r_U/r_S)$
RANITIDINE INJECTION	*USP Reference standards <11>*	*USP39–NF34*	5670	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of USP Ranitidine Related

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Compound C RS: Change *N* -[2-[[[5-[(Dimeth ylamino)methyl] -2-furanyl]methy l] su lfinyl]ethyl]-*N* -methyl-2-nitro- 1,1-ethenediami ne. to: *N* -{2-[({5-[(Dimeth ylamino)methyl] -2-furanyl}meth
TETRACYCLIN E HYDROCHL ORIDE CAPSULES	ASSAY/ *Procedure*	*USP39–NF34*	6082	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	*N* ?-methyl-2-nitro -1,1-ethenedia mine. Line 6 of *Sample solution*: Change dilute with *Diluent* to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volume. to: dilute with *Solution A* to volume.
VINPOCETINE	IMPURITIES/*Organic Impurities*	*USP39–NF34*	6880	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Footnote a of *Table 1*: Change Ethyl (12*RS*,13a*SR*,13b*SR*)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b-octahydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxylate (ethyl vincaminate). to: Ethyl (12*S*,13a*S*,13b*S*)-13a-ethyl-12-hydroxy-2,3

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								,5,6,12,13,13a,1 *H* -in dolo[3,2,1-*de*]py rido[3 ,2,1-*ij*][1,5]naphthyridi ne-12-carboxyla te (ethyl vincaminate). AND Footnoteb of *Table 1*: Change Methyl (13a*S*,13b*S*)-13a-ethyl-9-m ethoxy-2,3,5,6,1 3a,13b- hex ahydro -1*H* -in dolo[3,2,1-*de*]pyrido[3,2,1-ij][

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1,5]naphthyridine-12-carboxylate (apovincamine). to: Methyl (13a*S*,13b*S*)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1*H*-indolo[3,2,1-*de*]pyrido[3,2,1-*ij*][1,5]naphthyridine-12-carboxylate (apovincamine). AND Footnote d of *Table 1*: Change Ethyl (12*RS*,13a*RS*,13b*RS*)-13a-ethyl-2,3,5,6,12,13,13a,13b-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								octa hydro-1*H* -in dolo[3,2,1-*de*]py rido[3 ,2,1-*ij*][1,5]naphthyridi ne-12-carboxyla te (dihydrovinpo cetine). to: Ethyl (12*R*,13a*S* ,13b*S*)-13a-ethy l-2,3,5,6,12,13,1 3a,13b- octa hydro-1*H* -in dolo[3,2,1-*de*]py rido[3 ,2,1-*ij*][1,5]naphthyridi ne-12-carboxyla te (dihydrovinpo cetine).
REAGENTS,	REAGENTS/*6.*	*USP39–NF34*	2080	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	In the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INDICATORS AND SOLUTIONS	*General Tests for Reagents/6.2 Amino Nitrogen Test in Reagents*							numerator of the equation: Change 2.8 to: 14 AND Add × *f* AND Line 10: Change where %LOD is the percentage of loss on drying. to: where *f* is the correction factor obtained in the standardization of 0.2 N sodium hydroxide and %LOD is the percentage of loss on drying.
HAZARDOUS DRUGS—HANDLING IN HEALTHCARE SETTINGS	5. FACILITIES AND ENGINEERING CONTROLS/*5.3 Compounding*	*First Supplement to USP39–NF34*	7721	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	First bullet in second paragraph: Change • Be externally

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								vented through high-efficiency particulate air (HEPA) filtration to: • Be externally vented
IMIQUIMOD CREAM	IMPURITIES/*Organic Impurities*	*USP39–NF34*	4289	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Row 2 of Column 3 of *Table 2*: Change 1.5 to: 1.15 AND Row 3 of Column 3 of *Table 2*: Change 1.15 to: 1.5
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP39–NF34*	4766	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Test 3*: Change *Medium, Apparatus 1, Apparatus 2*, and *Analysis*: to: *Medium, Apparatus 1*,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								and *Apparatus 2*:
PALIPERIDONE	CHEMICAL INFORMATION	*USP39–NF34*	5253	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 5: Change (9*RS*)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one to: (9*RS*)-3-[2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]]ethyl]-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4*H*-pyrido[1,2-*a*]pyrimidin-4-one
RANITIDINE IN SODIUM CHLORIDE INJECTION	*USP Reference standards <11>*	*USP39–NF34*	5673	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of USP Ranitidine Related Compound C RS: Change *N*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl] su lfinyl]ethyl]-*N* -methyl-2-nitro-1,1-ethenediamine. to: *N* -{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth
CHONDROITIN SULFATE SODIUM, SHARK	SPECIFIC TESTS/*Clarity and Color of Solution*	*USP39–NF34*	6570	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	*N* ?-methyl-2-nitro-1,1-ethenediamine. Line 2 of *Instrumental conditions*: Change (See *Spectrophotometry and Light-Scattering <851>*.)

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: (See *Ultraviolet-Visible Spectroscopy* <*857*>.)
OLEYL ALCOHOL	ASSAY/ *Procedure*	*USP39–NF34*	7424	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Standard solution*: Change Prepare 1.0 mg/mL of USP Oleyl Alcohol RS in *Internal standard solution*, and heat the solution in a sealed container in a 50° water bath until oleyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of USP Oleyl Alcohol RS in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Internal standard solution AND Line 1 of *Sample solution*: Change Prepare 1.0 mg/mL of Oleyl Alcohol in *Internal standard solution*, and heat the solution in a sealed container in a 50° water bath until oleyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of Oleyl Alcohol in *Internal standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution
DIAZEPAM INJECTION	*Assay*	*USP39–NF34*	3445	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 7 of *Procedure*: 50C / $V(R_U / R_S)$ to: $50(C / V)(R_U / R_S)$
LORAZEPAM ORAL CONCENTRATE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4621	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: $C_{13}H_9Cl_2NO$
NICOTINE POLACRILEX	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	5061	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Add USP Polacrilex Resin RS
RANITIDINE ORAL SOLUTION	*USP Reference standards <11>*	*USP39–NF34*	5671	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of USP Ranitidine Related Compound C RS: Change *N* -[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl] su

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								lfinyl]ethyl]-*N* -methyl-2-nitro-1,1-ethenediamine. to: *N* -{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth
TROSPIUM CHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	6287	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	*N* ?-methyl-2-nitro-1,1-ethenediamine. Line 3 of USP Trospium Chloride Related Compound C RS:Change (1*R*,3*r*,5*S*)-3-Hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1?-pyrrolidinium] chloride. to: (1*R*,3*r*,5*S*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								)-3-Hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8,1?-pyrrolidinium] chloride, or (1*R*,3*r*,5*S*)-3-Hydroxyspiro[bicyclo[3.2.1]octane-8,1?-pyrrolidin]-1?-ium chloride.
CETYL ALCOHOL	IM PURITIES/*Limit of Related Fatty Alcohols*	*USP39–NF34*	7239	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Sample solution*: Change 1 mg/mL of Cetyl Alcohol in ethanol to: Prepare 1.0 mg/mL of Cetyl Alcohol in ethanol, and heat the solution in a sealed container in a 50° water bath until cetyl alcohol is dissolved. Allow

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the solution to cool to room temperature, and mix well.
ALPRAZOLAM EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>*	*USP39–NF34*	2389	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Variable definition list of second equation in *Test 2*/*Analysis*: Change V_S = volume of the *Sample solution* withdrawn at each time point and replaced with *Medium* (mL) to: V_S = volume of the *Sample solution* withdrawn at each time point (mL) AND Variable definition list of second equation in *Test 3*/*Analysis*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Change V_S = volume of the *Sample solution* withdrawn at each time point and replaced with *Medium* (mL) to: V_S = volume of the *Sample solution* withdrawn at each time point (mL)
PAROXETINE EXTENDED-RELEASE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP39–NF34*	8121	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	USP Paroxetine Related Compound B RS: Add $C_{19}H_{21}NO_3 \cdot HCl$ 347.84
LORAZEPAM	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP39–NF34*	4618	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of USP Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: C

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{13}H_9Cl_2NO$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MYCOPHENOLATE SODIUM	ASSAY/ *Procedure*	*USP39–NF34*	4965	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3: Change *Solvent A* to: *Solution A* AND Line 5: Change *Solvent B* to: *Solution B*
PALIPERIDONE	IMPURITIES/*Organic Impurities*/*System suitability*/*Suitability requirements*	*USP39–NF34*	5253	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Resolution*: Change hydroxybenzyl to: hydroxybenzoyl
SAMARIUM Sm 153 LEXIDRONAM INJECTION	*Other requirements*	*USP39–NF34*	5791	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1: Change *Injections and Implanted Drug Products <1>*; not subject to *Container Content*. to: Meets the requirements of *Injections and Implanted Drug Products <1>*; not subject to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Container content.
CHONDROITIN SULFATE SODIUM, SHARK	COMPOSITION /*Disaccharide Composition*	*USP39–NF34*	6570	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of *Chondroitinase ABC solution*: Change 10.0 mL of *Buffer solution* to: 1.0 mL of *Buffer solution* AND Line 4 of *Analysis*: Change and 1.0 mL to: and 0.1 mL
SEMISOLID DRUG PRODUCTS—PERFORMANCE TESTS	IN VITRO PERFORMANCE TESTS	*USP39–NF34*	1869	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 7 of *Application of Drug Release*: Change The individual amounts of drug released from *R* is plotted versus time, to: The individual amounts of drug released from *R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								are plotted versus the square root of time,
SODIUM CETO STEARYL SULFATE	IM PURITIES/*Limit of Sodium Chloride and Sodium Sulfate*/*Sodium sulfate/ Titrimetric system*	*USP39–NF34*	7518	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Endpoint detection*: Change Potentiometric to: Visual
DICLOFENAC SODIUM EXTE NDED-RELEASE TABLETS	IM PUR ITIES/*Organic Impurities*	*USP39–NF34*	3460	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Standard solution*: Change 0.001 mg/mL of USP Diclofenac Sodium RS in *Diluent* to: 0.001 mg/mL each of USP Diclofenac Sodium RS and USP Diclofenac Related Compound A RS in *Diluent*
LORAZEPAM	ADDITIONAL R	*USP39–NF34*	4622	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TABLETS	EQUIREMENTS/*USP Reference Standards RS <11>*							Lorazepam Related Compound B RS: Change $C_{13}H_9ClNO$ to: $C_{13}H_9Cl_2NO$
OXANDROLONE TABLETS	*Dissolution <711>/Test 3*	*USP39–NF34*	5193	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *Chromatographic system*: Change 30-cm column to: 3-cm column
RANITIDINE TABLETS	*USP Reference standards <11>*	*USP39–NF34*	5672	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of USP Ranitidine Related Compound C RS: Change *N* -[2-[[[5-[(Dimethylamino)methyl]-2-furanyl]methyl] su lfinyl]ethyl]-*N* -methyl-2-nitro-1,1-ethenediamine. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								N-{2-[({5-[(Dimethylamino)methyl]-2-furanyl}meth
								N-?-methyl-2-nitro-1,1-ethenediamine.
CHONDROITIN SULFATE SODIUM, SHARK	IMPURITIES/*Limit of Protein*	*USP39–NF34*	6570	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 2 of *Instrumental conditions*: Change (See *Spectrophotometry and Light-Scattering* <*851*>.) to: (See *Ultraviolet-Visible Spectroscopy* <*857*>.)
MYRISTYL ALCOHOL	ASSAY/*Procedure*	*USP39–NF34*	7413	27-May-2016	1-Jun-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of *Standard solution*: Change Prepare 1.0 mg/mL of USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Myristyl Alcohol RS in *Internal standard solution*, and heat the solution in a sealed container in a 50° water bath until myristyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of USP Myristyl Alcohol RS in *Internal standard solution* AND Line 1 of *Sample solution*: Change Prepare 1.0 mg/mL of Myristyl Alcohol

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								in *Internal standard solution*, and heat the solution in a sealed container in a 50° water bath until myristyl alcohol is dissolved. Allow the solution to cool to room temperature, and mix well. to: 1.0 mg/mL of Myristyl Alcohol in *Internal standard solution*
SELENOMETHIONINE	CHEMICAL INFORMATION	*USP38–NF33*	6226	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 3: Change [1464-42-2] to: [3211-76-5]
PLASTIC MATERIALS OF CONSTRUCTION	TEST METHODS/ *Extractions*/*Table 3*	*USP39–NF34*	493	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of footnote b: Change For nonplasticized polyethylene

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								only. to: For polyethylene only.
FLUTICASONE PROPIONATE AND SALMETEROL INHALATION POWDER	ASSAY/ *Procedure*	*USP39–NF34*	4020	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 3 of *System suitability*: Change for salmeterol and fluticasone propionate are to: for fluticasone propionate and salmeterol are
CONTAINERS--PERFORMANCE TESTING	MOISTURE VAPOR TRANSMISSION/*Packaging System Classification for Multiple-Unit Containers and Unit-Dose Containers for Liquid Oral Dosage Forms/ Procedure*	*USP38–NF33*	465	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of the Equation: Change $[(W_{1i} ? W_T) ? (W_{14i} ? W_T) ? (W_{C1} ? W_{C14})] \times 365 \times \{[100/(W_{1i} ? W_T)] \times 14\}$ to: $[(W_{1i} ? W_T) ? (W_{14i} ? W_T) ? (W_{C1} ? W_{C14})] \times 365 \times 100/(W_{1i} ? W_T) \times 14$
PLASTIC	SPECIFICATIO	*USP39–NF34*	493	25-Mar-2016	1-Apr-2016	*USP40–NF35*	*USP40–NF35*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
MATERIALS OF CONSTRUCTION	NS/ *Polyethylene Terephthalate and Polyethylene Terephthalate G/Extractable Metals*							*Titanium*: Change 0.1 µg/g. to: 1 µg/g.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 22
- Page 23
- Page 24
- Page 25
- Page 26
- Page 27
- Page 28
- Page 29
- Page 30
- …
- Next page Next ›
- Last page Last »